Adjunctive Intranasal Esketamine for Comorbid Treatment-Resistant Depression with Suicidal Ideation in Patients Receiving Palliative Care at a Comprehensive Cancer Center: A Case Series.
Journal of palliative medicine January 1, 2025 Mercy Tomy, William Alexander, Sanjay Gupta et al. 4 citations
Three patients with cancer, treatment-resistant depression, and suicidal ideation received intranasal esketamine (Spravato®) at a palliative care clinic. After treatment, all three had substantial reductions in depression severity and no further suicidal ideation, with improvements lasting up to a year. No serious adverse events occurred. The cases suggest intranasal esketamine may be a useful option for treating depression and suicidal thoughts in palliative care.